Compare Novartis with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs JUBILANT LIFE SCIENCES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS JUBILANT LIFE SCIENCES NOVARTIS/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 485.8 16.1 3,016.1% View Chart
P/BV x 28.2 1.9 1,498.2% View Chart
Dividend Yield % 1.6 0.8 204.8%  

Financials

 NOVARTIS   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
NOVARTIS/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs758898 84.4%   
Low Rs579618 93.8%   
Sales per share (Unadj.) Rs228.4572.0 39.9%  
Earnings per share (Unadj.) Rs31.736.2 87.6%  
Cash flow per share (Unadj.) Rs32.859.5 55.1%  
Dividends per share (Unadj.) Rs10.004.50 222.2%  
Dividend yield (eoy) %1.50.6 251.9%  
Book value per share (Unadj.) Rs297.1301.9 98.4%  
Shares outstanding (eoy) m24.69159.28 15.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.3 221.0%   
Avg P/E ratio x21.120.9 100.7%  
P/CF ratio (eoy) x20.412.7 160.3%  
Price / Book Value ratio x2.22.5 89.6%  
Dividend payout %31.512.4 253.7%   
Avg Mkt Cap Rs m16,505120,694 13.7%   
No. of employees `0000.72.4 27.9%   
Total wages/salary Rs m1,44519,260 7.5%   
Avg. sales/employee Rs Th8,441.338,120.6 22.1%   
Avg. wages/employee Rs Th2,163.68,058.4 26.8%   
Avg. net profit/employee Rs Th1,173.12,414.3 48.6%   
INCOME DATA
Net Sales Rs m5,63991,108 6.2%  
Other income Rs m1,718357 480.8%   
Total revenues Rs m7,35791,466 8.0%   
Gross profit Rs m-6317,390 -0.4%  
Depreciation Rs m253,709 0.7%   
Interest Rs m552,198 2.5%   
Profit before tax Rs m1,57511,840 13.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m7923,268 24.2%   
Profit after tax Rs m7845,770 13.6%  
Gross profit margin %-1.119.1 -5.8%  
Effective tax rate %50.327.6 182.1%   
Net profit margin %13.96.3 219.4%  
BALANCE SHEET DATA
Current assets Rs m9,52245,848 20.8%   
Current liabilities Rs m3,29620,897 15.8%   
Net working cap to sales %110.427.4 403.1%  
Current ratio x2.92.2 131.7%  
Inventory Days Days3757 64.5%  
Debtors Days Days2851 55.8%  
Net fixed assets Rs m4665,498 0.1%   
Share capital Rs m123159 77.5%   
"Free" reserves Rs m7,21347,930 15.0%   
Net worth Rs m7,33648,089 15.3%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m11,105114,685 9.7%  
Interest coverage x29.56.4 461.7%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.50.8 63.9%   
Return on assets %7.66.9 108.7%  
Return on equity %10.712.0 89.0%  
Return on capital %22.212.4 179.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6112,422 0.5%   
Fx outflow Rs m3,63017,227 21.1%   
Net fx Rs m-3,570-4,805 74.3%   
CASH FLOW
From Operations Rs m1,61011,215 14.4%  
From Investments Rs m687-10,118 -6.8%  
From Financial Activity Rs m-2,6776,574 -40.7%  
Net Cashflow Rs m-3807,612 -5.0%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 2.0 8.7 23.0%  
FIIs % 1.6 21.2 7.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 21.1 101.9%  
Shareholders   41,647 23,815 174.9%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 23, 2019 12:47 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - DISHMAN PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS